Format

Send to

Choose Destination
Oncogene. 2018 Mar;37(9):1121-1141. doi: 10.1038/s41388-017-0024-z. Epub 2017 Dec 15.

Immunotherapies for malignant glioma.

Author information

1
Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
2
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
3
Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA, USA.
4
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. acharest@bidmc.harvard.edu.
5
Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA, USA. acharest@bidmc.harvard.edu.
6
Division of Genetics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. acharest@bidmc.harvard.edu.

Abstract

Glioblastoma multiforme (GBM) is a highly malignant primary brain cancer with a dreadful overall survival and for which treatment options are limited. Recent breakthroughs in novel immune-related treatment strategies for cancer have spurred interests in usurping the power of the patient's immune system to recognize and eliminate GBM. Here, we discuss the unique properties of GBM's tumor microenvironment, the effects of GBM standard on care therapy on tumor-associated immune cells, and review several approaches aimed at therapeutically targeting the immune system for GBM treatment. We believe that a comprehensive understanding of the intricate micro-environmental landscape of GBM will abound into the development of novel immunotherapy strategies for GBM patients.

PMID:
29242608
PMCID:
PMC5828703
DOI:
10.1038/s41388-017-0024-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center